Introduction
Pancreatic cancer poses a high mortality burden in the United States, and current therapies have modestly improved survival (1) (2) (3) (4) (5) (6) . The impetus for exploring chronic disease medications for use in anticancer approaches is to advance new therapeutic strategies into clinical settings with relatively short regulatory evaluation timelines. Among medications being evaluated, metformin and statins are two frequently prescribed drugs with an established safety profile that show promising anti-cancer effects (7, 8) , although their efficacy in pancreatic cancer treatment remains unclear.
Beneficial effects of metformin and statins on pancreatic cancer treatment are biologically plausible (9-13), although findings from epidemiological studies on their therapeutic benefits have been inconsistent. Our recent meta-analysis included ten publications on metformin treatment and six publications on statin treatment and found that each medication was associated with improved overall survival in pancreatic cancer patients (14) . However, some critical issues have not been addressed. First, dyslipidemia is more prevalent in diabetic patients, and the majority of metformin users also take lipid-lowering drugs such as statins (15) (16) (17) . Therefore, the survival benefits observed in metformin users may in part be due to the statin use. Moreover, there are few studies that examined the interactive or potential joint effect of combination treatments of metformin and statins (18, 19) . Second, misclassification or disregard of immortal time (period of cohort entry and date of first exposure to a drug during which death or an outcome under study could not occur) may introduce unintended bias, which leads to the overestimation of drug effects (20) . Several retrospective cohort studies were likely to have suffered from this bias because use of metformin or statin was dichotomized into ever/never categories without taking into account timing of drug use in relation to cohort entry (18, (21) (22) (23) .
Third, previous studies were unable to distinguish the effects of pre-diagnosis drug use (medications initiated before diagnosis) versus post-diagnosis drug use (medications initiated after diagnosis), and which have been demonstrated in recent studies, such as those using data from the Women's Health Initiative (24). Previous 5 epidemiological studies on metformin and statins include mostly pre-diagnosis users, and very few include post-diagnosis users. To address the "healthy user effect" (25) , the pre-diagnosis users should be analyzed separately from post-diagnosis users. Finally, questions regarding how drug initiation and dosages impact on mortality among pancreatic cancer patients remain unanswered. It is therefore important to examine the treatment effect of optimal therapeutic regimens in observational studies.
To inform future trial design and effective clinical practice, these critical issues were examined in a large cohort population with more rigorous approaches. We used a nationally representative cancer database in the United States to determine the differential and joint effects of metformin and statin use on the survival outcomes among elderly pancreatic cancer patients.
Materials and Methods

Study population
After approval by the Institutional Review Board at Rutgers University, this study was performed using the 8500, 8521, 8050, 8260, 8441, 8450, 8453, 8470, 8471, 8472, 8473, 8480, 8481, 8503 (https://seer.cancer.gov/icd-o-3/). The detailed patient selection steps are illustrated in Figure 1 . Briefly, we excluded patients with non-primary pancreatic cancer or non-adenocarcinoma histology, or patients in HMO (health-care maintenance organizations). Patients diagnosed at autopsy or with missing diagnosis date or death date equal to or less than diagnosis date were also excluded from the study cohort. To include comorbidity characteristics before cancer diagnosis and treatment characteristics present in inpatient and outpatient claim files, we restricted the analysis dataset to patients who were continuously enrolled in Medicare Part A and Part B from 12 months before cancer diagnosis until death or December 30, 2012, the last date of available Medicare claims data. To capture the potential drug effect up to 3 months before cancer diagnosis and the outcomes after cancer diagnosis, we further restricted our dataset to patients who were continuously enrolled in Medicare Part D beginning 3 months before cancer diagnosis to death or the end of follow up.
Sociodemographic and clinical characteristics and comorbidities
Sociodemographic information, including age, sex, race, and neighborhood income, were obtained from the SEER-Medicare linked databases. We controlled the burden of comorbidities, including cardiovascular disease and chronic kidney disease, using the Deyo adaption of Charlson comorbidity index (26) (27) (28) . The
Charlson comorbidity conditions were identified using inpatient and outpatient hospital claims (Medicare Provider Analysis and Review, Outpatient Standard Analytical File) as well as claim files by individual physicians (Carrier File) (28, 29) . To avoid overestimating comorbidity related to PDAC diagnosis, we used the claims in the 11 months prior to cancer diagnosis to calculate the Charlson score. The diabetic comorbidity severity index (DCSI) of diabetic or Impaired Glucose Tolerance (IGT) patients was used to adjust for diabetic severity for predicting mortality (30, 31) . Due to the lack of smoking information, we used chronic obstructive pulmonary disease (COPD) as a surrogate for smoking-related illness (32) . Tumor characteristics, including tumor grade, stage and size, were ascertained from the SEER registry database. Treatment information, including resection, radiation, and chemotherapy, was identified from the Medicare Claims (Medicare Provider Analysis and Review, Carrier, Outpatient Standard Analytical File) using the International Classification of Disease, 9 th Revision (ICD-9) and the Healthcare Common Procedure Coding System codes (33) .
Metformin and statin regimens
Metformin and statin regimens were extracted from the Medicare Part D Claims file. Daily intensity for metformin was estimated as total milligrams dispensed divided by total days of prescriptions before cancer diagnosis. Statins were categorized based on drug characteristics as: lipophilic (atorvastatin, fluvastatin, lovastatin, and simvastatin); hydrophilic (pravastatin and rosuvastatin); high potency (atorvastatin, rosuvastatin, and simvastatin); or low potency (fluvastatin, lovastatin, and pravastatin) (34). Statin intensity was assessed as an ordinal variable (high, moderate, and low) according to average daily dose lowering of low-density lipoprotein cholesterol (35) .
Statistical analysis
Demographic and clinical characteristics, along with comorbid conditions, were compared among four groups: metformin alone, statin alone, dual users and neither users using Chi-square tests. Overall PDAC survival was assessed with survival times calculated as the time from diagnosis to death, or censored at the end of followup. Propensity scores (36) were used to estimate the probability of one of the following four exclusive medication use categories: "ever used statin" (p1), 'ever used metformin' (p2), 'ever used both statin and metformin' (p3) and 'none'. They were calculated based on patients' sociodemographic characteristics, and comorbidities (Charlson Comorbidity Score, obesity, chronic pancreatitis, dyslipidemia, and diabetes/IGT) using a general (polytomous) logistic regression model (37) . To control pre-treatment imbalances on observed variables, propensity scores p1, p2 and p3 were included as covariates in the statistical models for propensity score adjustment. Comorbidity Score. We developed the final model by adjusting for tumor characteristics, treatment characteristics, and propensity scores, as well as the variables that remained imbalanced after propensity score adjustment (i.e., dyslipidemia, diabetes/IGT, Charlson Comorbidity Score).
To assess the possible effect modification by diabetes/IGT, dyslipidemia or tumor characteristics, we performed stratified analyses by diabetes/IGT and dyslipidemia as well as tumor stage, grade and tumor size.
Additionally, we determined the differential effects on survival for pre-diagnosis users versus post-diagnosis users, by stratified medication use before and after cancer diagnosis. Furthermore, subset analyses were conducted to assess the effects of metformin use (timing initiation and daily intensity) and statin use (timing initiation, name, type, potency and intensity) among patients who initiated medications before cancer diagnosis. When we assessed the metformin effect on overall survival, statin use was adjusted as a timevarying covariate. Similarly, we adjusted metformin use to assess statin effect. All statistical analyses were performed using SAS Version 9.4 (SAS Institute in Cary. NC).
Results
A total of 12,572 patients with primary PDAC composed the analytic population for the study (Figure 1 Before adjustment using the propensity score, there were significant differences on almost all studied variables among the four groups (Table 1) . Metformin alone, statin alone, and dual users were significantly younger than neither users. Statin alone and dual users had a higher proportion of males, lower localized/regional tumor stage and smaller tumor size, compared to neither users. Additionally, metformin alone had higher proportion of chemotherapy and radiation therapy than neither users. Not surprisingly, a higher frequency of patients with dyslipidemia or diabetes/IGT, used either metformin, or statin, or both. After propensity score adjustment, only age, Charlson Comorbidity Score, dyslipidemia, and diabetes/IGT, could not be wellbalanced among the four groups (Table 1 ).
In However, the association of overall survival with the exposure to metformin alone or a combination remained non-significant (Table 2 ). When we restricted our population to patients who had survived for greater than 2 months (N = 8274), we observed a weaker and non-significant association between statin use and overall survival (HR, 0.96; 95% CI, 0.91 ̶ 1.01) (Supplementary Table S1 ), suggesting that the contribution of statins to survival may be mitigated with time.
When stratified by the status of diabetes/IGT or dyslipidemia, we observed similar patterns of results, and no evidence that diabetes/IGT or dyslipidemia modify effects of statins (Pinteraction > 0.05) (Supplementary Table   S2 ). Additionally, we performed stratified analyses on tumor stage, grade, and size to confirm the statin effect.
Statin use showed a significant association with improved overall survival among patients with distant tumor stage or III/IV tumor grade, but no effect modification by tumor size was observed (Supplementary Table S3 ).
When we stratified medication use before and after cancer diagnosis, the median survival among pre-and Table 3) .
Compared with non-metformin users, patients who used metformin either > 6 months or ≤ 6 months before diagnosis did not have longer survival, however, using metformin 1,000 ̶ 1,500 mg/day was significantly associated with an increased overall mortality (HR, 1.10; 95% CI, 1.03 ̶ 1.17) ( Table 4 ). The trend of HR from low to high statin intensity was borderline significant (P = 0.07).
Discussion
To our knowledge, this is the largest US-population based study to examine the differential and joint effects of metformin and statins on survival among pancreatic cancer patients. We found that exposure to statins, rather than metformin, is associated with an improved overall survival of elderly pancreatic cancer patients. In particular, post-diagnosis exposure to statins is associated with a 31% reduction in mortality, and prediagnosis exposure to statins with a 6% reduction in mortality. Furthermore, the effect of rosuvastatin (the statin with the longest half-life) is most pronounced. These new insights provide crucial data for planning randomized clinical trials using statins as an adjuvant treatment of pancreatic cancer.
Findings from previous epidemiological studies of metformin use and pancreatic cancer survival are conflicting. Possible explanations include failure to consider diabetic severity and comorbidities (38) , statin use (39), and immortal time bias (40) . When accounting for these critical issues, we observed that metformin use was not significantly associated with overall survival, either in pre-diagnosis users or in post-diagnosis users. Our results are consistent with a recent retrospective cohort study of 980 PDAC patients with diabetes when the analysis was performed by using time-varying Cox model (41) . These results suggested that the metformin exposure variable is better treated as a time-dependent variable rather than a fixed-time variable (42) . In this current study, we acknowledge that we may not have had sufficient power to detect smaller effects due to the limited sample sizes in our subgroup analysis: only 497 patients started metformin ≤ 6 months before diagnosis, and 700 patients used less than 1,000 mg/day of metformin.
We observed that statin use was significantly associated with improved overall survival of elderly PDAC patients, and this finding was more pronounced in post-diagnosis statin users. A retrospective study that halting cell cycle progression and proliferation (45); increasing radiosensitization in cancer cells (46); promoting apoptosis (47, 48) ; and impairing metastasis of tumors (49) . Based on our current understanding of the diverse molecular pathways of statin action, a protective effect of statins on overall survival of pancreatic cancer patients is biologically plausible. Unexpectedly, the current study did not observe a survival benefit for dual users. This might be explained by a higher Charlson comorbidity score and a higher proportion of obesity and diabetes/IGT in dual users, compare to patients with statin alone. The potential anti-tumor benefits of statins should be carefully further assessed in preclinical and clinical studies to repurpose statins for the treatment of pancreatic cancer.
We observed that that rosuvastatin significantly improved overall survival, while other statins did not.
Although the mechanisms are unknown, it is worth noting that the half-life elimination of rosuvastatin is much longer (about 20 hours), compared to a half-life of all other statins (which range from 2 and 3 hours).
Interestingly, it has been showed that mice xenotransplanted with pancreatic cancer cells and treated with rosuvastatin had higher survival rates, compared to the mice treated with other commercially available statins (50) . In addition, we found that hydrophilic and high potency statins exerted better survival outcomes than 13 non-statin use. These may be due to many factors such as different chemical structures leading to changes in their bioavailability, pharmacokinetics, and pharmacodynamics (51).
We also found low and moderate intensity of statin use improved survival significantly, but high intensity statin showed a non-significant survival benefit. The marked differences were partially due to lowering LDL-C strengths among different intensities, indicating a contribution of downstream intermediates in cholesterol biosynthesis for growth and viability of pancreatic cells. It is possible that the patients using high intensity statin might have worse hyperlipidemia, and therefore no survival benefit was observed for patients with high intensity statin. Our findings are comparable with those in a recent Kaiser Permanente South California (KPSC) study by Huang et al. (52) . They reported a 13% and 12% reduction in mortality during study period among any statin users and among pre-diagnosis statin users, respectively. Further, they found that simvastatin and atorvastatin were the only two medications that were independently associated with improved survival.
However, the sample size of the KPSC study was too small to evaluate the effect of rosuvastatin and postdiagnosis statin use.
Several limitations inherent with our data must be addressed. First, the study is limited by its retrospective design and is not a randomized clinical trial. Drug exposures are dependent on other factors related to elderly patients' baseline health. To address this issue, we used propensity scores to estimate the likelihood that patients would use metformin and/or statin. The propensity scores controlled for selection bias that could occur as a result of imbalances of comorbidities and sociodemographic factors (36 
